ARA-290

Name: ARA-290
Brand: PeptideValidation.com
Availability: OutOfStock

ARA-290 Recovery, Healing & Tissue Repair Peptides

ARA-290 (Cibinetide) is a groundbreaking, first-in-class Innate Repair Receptor (IRR) agonist designed to support profound nerve regeneration, combat systemic inflammation, and facilitate advanced tissue repair. By uniquely targeting the body's intrinsic cellular survival pathways, it offers unprecedented efficacy in treating small fiber neuropathy, reducing neuropathic pain, and accelerating recovery from metabolic and inflammatory damage.

Access Certified Vendors View Testing Standards

View full details

Quick Facts

ARA-290 (Cibinetide) is a groundbreaking, first-in-class Innate Repair Receptor (IRR) agonist designedto support profound nerve regeneration, combat systemic inflammation, and facilitate advanced tissuerepair. By uniquely targeting the body's intrinsic cellular survival pathways, it offers unprecedentedefficacy in treating small fiber neuropathy, reducing neuropathic pain, and accelerating recovery frommetabolic and inflammatory damage.

Generic Name

ARA-290 (Cibinetide)

Drug Class

Innate Repair Receptor (IRR) Agonist

Administration

Subcutaneous Injection

FDA Approval

Orphan Drug Designation (Investigational)

Typical Maintenance Dose

2mg to 4mg

Starting Dose

2mg daily

Injection Sites

Abdomen, Thigh, near localized nerve injury

Treatment Duration

Short to medium-term cycles (4-12 weeks)

Storage

Refrigerated (2°C - 8°C) once reconstituted

Prescription Required

Yes

Average Outcome

Significant reduction in neuropathic pain and nerve fiber regrowth

Best For

Small fiber neuropathy, chronic pain, and systemic inflammation

What Is Retatrutide?

Retatrutide (LY3437943) is an investigational peptide that belongs to a class of compounds known as triple receptor agonists. It is designed to activate three key metabolic hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors.Retatrutide is being studied in metabolic and obesity-related research because of its unique multi-receptor mechanism of action. Unlike traditional single-pathway compounds, Retatrutide targets multiple metabolic signaling pathways that researchers believe may influence appetite regulation, energy expenditure, glucose metabolism, and body weight.Developed by Eli Lilly and Company, Retatrutide has become one of the most widely discussed investigational peptides in metabolic research and is currently being evaluated in ongoing clinical studies. Retatrutide is a novel triple agonist peptide targeting the GLP-1, GIP, and glucagon receptors simultaneously.

Retatrutide (LY3437943) is a novel investigational peptide developed by Eli Lilly and Company. It is classified as a triple agonist, meaning it simultaneously activates three distinct hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This triple-receptor engagement sets Retatrutide apart from every other metabolic research peptide currently in development or on the market.

As of 2023, Retatrutide has demonstrated unprecedented weight loss outcomes in Phase 2 clinical trials, with participants achieving a mean body weight reduction of up to 24.2% over 48 weeks — making it the most effective weight loss compound ever tested in a randomized controlled trial at the time of publication.

How Does Retatrutide Work?

Retatrutide works by binding to and activating three key metabolic hormone receptors in the body. Each receptor plays a distinct role in energy metabolism, appetite regulation, and glucose homeostasis. By engaging all three simultaneously, Retatrutide creates a synergistic effect that exceeds what any single or dual agonist can achieve.

Why Was Retatrutide Developed?

Retatrutide was developed to address the limitations of first and second generation metabolic peptides. While semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP) demonstrated significant efficacy, researchers hypothesized that adding glucagon receptor activity could further enhance energy expenditure through thermogenesis and hepatic fat reduction.

What Receptors Does It Target?

GLP-1 Receptor — Controls insulin secretion, slows gastric emptying, and signals satiety to the brain
GIP Receptor — Enhances insulin sensitivity, augments GLP-1 effects, and modulates lipid metabolism
Glucagon Receptor — Increases energy expenditure via thermogenesis and reduces hepatic fat accumulation

How Is Retatrutide Different From Other Peptides?

Only peptide in development targeting GLP-1, GIP AND glucagon simultaneously
Highest weight loss outcomes ever recorded in a randomized controlled trial (24.2%)
Significant reduction in liver fat — addressing NAFLD and metabolic liver disease
Improvements in cardiometabolic markers including blood pressure and lipid profiles
Once-weekly subcutaneous injection with a favorable tolerability profile

💉 Receptor Target

GLP-1 Receptor

Stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and activates satiety pathways in the hypothalamus to reduce food intake.

⚡ Receptor Target

GIP Receptor

Enhances glucose-stimulated insulin secretion, improves insulin sensitivity in peripheral tissues, augments GLP-1 activity, and modulates lipid metabolism and adipose tissue function.

🔥 Receptor Target

Glucagon Receptor

Increases hepatic glucose production, stimulates thermogenesis and energy expenditure, promotes lipolysis, and directly reduces liver fat — a key differentiator from GLP-1/GIP dual agonists.

The simultaneous activation of all three receptors creates a synergistic metabolic effect that exceeds single-receptor targeting alone.

ARA-290 Research Studies

Published clinical and preclinical research on ARA-290 .

Corneal Nerve Fiber Regrowth Trial

ARA-290 Corneal Nerve Fiber Regrowth Trial

In comprehensive clinical trials involving patients with Sarcoidosis-associated small fiber neuropathy, ARA-290 demonstrated the unprecedented ability to physically stimulate the regrowth of small nerve fibers, objectively measured via corneal confocal microscopy over a 28-day treatment period.

Neuropathic Pain Reduction

ARA-290 Neuropathic Pain Reduction

Phase 2b clinical trials have consistently shown statistically significant reductions in patient- reported pain scores, alongside improvements in tactile sensitivity and a measurable decrease in autonomic dysfunction and burning pain.

Immunomodulation Outcomes2023

ARA-290 Immunomodulation Outcomes

Research indicates rapid shifts in immune profiles, specifically down-regulating systemic inflammatory markers (like TNF-alpha) while upregulating anti-apoptotic cellular survival pathways in the presence of metabolic stress.

Retatrutide vs Other Peptides

How does Retatrutide compare to other leading research peptides?

Feature	Semaglutide	Tirzepatide	Liraglutide
Weekly Injection	Yes	Yes	Daily
Appetite Control	Excellent	Excellent	Moderate
Average Weight Loss	15-17%	20%+	6-8%
Dosing Frequency	Weekly	Weekly	Daily
Blood Sugar Support	Yes	Yes	Yes
Long-Term Data	Extensive	Growing	Established
Convenience	High	High	Moderate

Tirzepatide vs Semaglutide

Tirzepatide may produce greater weight loss due to its dual-agonist mechanism (GIP + GLP-1).
Semaglutide currently has longer-term weight management data available.
Both medications require physician supervision and dose titration.

Tirzepatide vs Liraglutide

Tirzepatide requires only weekly injections, whereas Liraglutide requires daily administration.
Tirzepatide produces vastly superior weight reduction (20%+ compared to Liraglutide's 6-8%).

PeptideValidation Testing & Validation

Every product undergoes rigorous multi-layer laboratory validation.

🔬

Medical History

History of diagnosed neuropathy, including nerve conduction studies or skin biopsies.
Current status of autoimmune diseases, specifically Sarcoidosis or diabetes mellitus.
Review of current pain management regimens and physiological responses to previous therapies.

🔬

Laboratory Testing

Comprehensive Metabolic Panel (CMP) and Complete Blood Count (CBC).
Hemoglobin A1c (HbA1c) to assess diabetic control.
Inflammatory markers (CRP, ESR, and specific cytokine panels if available).
Quantitative Sudomotor Axon Reflex Test (QSART) or skin biopsy for SFN baseline.

🔬

Monitoring During Treatment

MDT

Subjective pain scale tracking and autonomic symptom improvements.
Changes in tactile sensitivity and temperature regulation in extremities.
Overall fatigue levels and improvements in functional daily activities.
Periodic evaluation every 4 weeks to adjust dosing protocols and measure regenerative progress.

Frequently Asked Questions

Everything you need to know about peptide testing, certification, and compliance.

How quickly does ARA-290 work?

While some patients report a muting of severe neuropathic pain within the first 1-2 weeks, actual
structural nerve regeneration takes time. Most measurable clinical improvements in nerve function and
sustained pain reduction are evaluated after a continuous 4-week to 8-week cycle.

Does ARA-290 increase red blood cells like EPO?

No. This is the defining characteristic of ARA-290. It was molecularly engineered to lack the
hematopoietic properties of natural EPO, meaning it provides the profound tissue healing and anti-
inflammatory benefits without dangerously elevating your red blood cell count or causing cardiovascular
stress.

Can I combine ARA-290 with my current pain medications?

In many cases, yes. ARA-290 is often used adjunctively. However, as ARA-290 actively repairs the
nerves and lowers pain levels, patients often find they can work with their prescribing physician to
gradually taper off harsh neurological pain medications like Gabapentin.

Is ARA-290 an ongoing, lifelong medication?

Unlike standard pain management pills which require lifelong daily use to suppress symptoms,
ARA-290 is typically administered in regenerative cycles. Because it actively repairs the damaged
tissue, many patients can take breaks from the therapy once structural integrity is restored, returning to
it only if symptoms flare up.

Does it require refrigeration?

Yes. As a highly sensitive peptide sequence, the lyophilized powder should be stored away from light,
and once reconstituted with bacteriostatic water, it must be kept refrigerated (between 2°C and 8°C) to
maintain maximum potency and stability.

Certification Standards

Certified Vendor Requirements

To qualify as a PeptideValidation.com Certified Vendor, companies must meet our rigorous multi-step testing and documentation standards. Certification is not bought — it is earned through independent verification.

🏆 Apply for Certification

To qualify, vendors must:

📦

Submit Batch Testing
Vendors must submit product samples for independent third-party lab testing before listing.
✅

Pass Purity Requirements
All products must meet minimum purity thresholds verified by HPLC analysis.
🔬

Verify Identity via LC-MS
Molecular identity of each compound confirmed through liquid chromatography-mass spectrometry.
📄

Maintain Full Documentation
COAs, batch records, and testing documentation must be publicly available on the vendor profile.
🔄

Undergo Quarterly Re-Testing
Certification requires mandatory re-testing every quarter to maintain active certified status.